Baidu
map

AJKD:乙酰唑胺联合氢氯噻嗪继之使用呋塞米vs呋塞米联合氢氯噻嗪继之使用呋塞米治疗成人肾性水肿的疗效对比

2021-09-15 从医路漫漫 MedSci原创

如果最大或接近最大剂量的袢状利尿剂治疗肾性水肿无效,则被认为是难治性的肾性水肿。这种情况可以用袢利尿剂和噻嗪类药物治疗。

背景:如果最大或接近最大剂量的袢状利尿剂治疗肾性水肿无效,则被认为是难治性的肾性水肿。这种情况可以用袢利尿剂和噻嗪类药物治疗。然而,动物研究表明,乙酰唑胺和氢氯噻嗪同时减少对氯化钠转运体的抑制可产生显著的利尿作用,在服用该药后给予速尿可增强速尿的利尿作用。因此,我们进行了这项研究,乙酰唑胺联合氢氯噻嗪继之使用呋塞米对比呋塞米联合氢氯噻嗪继之使用呋塞米治疗成人肾性水肿的疗效

方法:选择20例顽固性肾性水肿患者,他们每日服用速尿80 mg,肌酐清除率为60mL/min。将这些患者随机分为2组:第1组(N=10)给予乙酰唑胺250 mg/d,氢氯噻嗪50 mg/d;第2组(N=10)给予速尿40 mg/d,氢氯噻嗪50 mg/d,疗程1周;第2阶段,两组均给予速尿40 mg/d,疗程2周。

结果:主要对比结果是在每个阶段结束前和结束时体重的绝对变化。测量基线和每一阶段结束时的体重和24小时尿量。结果显示,在第1阶段(-1.4±0.52 vs -0.65±0.41kg;P=0.001)和第2阶段(-1.66±0.84 vs -0.56±0.47kg;P=0.005)结束时,1组的平均体重下降幅度显著大于2组,在第2阶段结束时,第1组的24小时尿量增加的也明显更多。存在的局限是样本量小,随访时间短,缺乏血清碳酸氢盐和氯化物的测定

表 两组从基线到第1周结束和从第1周到第3周结束的变化以及组间的差异

图1 体重(kg)与研究时间(周)的变化。缩写:HCTZ,氢氯噻嗪;SD,标准差。

图2 24小时尿量(mL/d)与研究时间(周)的变化。缩写:HCTZ,氢氯噻嗪;SD,标准差。

图3 24小时尿钠(mEq/d)与研究时间(周)的变化。缩写:HCTZ,氢氯噻嗪;SD,标准差。

结论:乙酰唑胺联合氢氯噻嗪继之使用呋塞米治疗难治性肾病水肿疗效优于呋塞米联合氢氯噻嗪继之使用呋塞米

原文出处

Fallahzadeh MA,  Dormanesh B,  Fallahzadeh MK,et al,Acetazolamide and Hydrochlorothiazide Followed by Furosemide Versus Furosemide and Hydrochlorothiazide Followed by Furosemide for the Treatment of Adults With Nephrotic Edema: A Randomized Trial.Am J Kidney Dis 2017 Mar;69(3) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643237, encodeId=18fc164323e89, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Oct 06 10:11:41 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333489, encodeId=0b681333489e7, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360552, encodeId=bee113605529a, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417346, encodeId=7987141e34613, content=<a href='/topic/show?id=a2b0394892b' target=_blank style='color:#2F92EE;'>#呋塞米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39489, encryptionId=a2b0394892b, topicName=呋塞米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befb3261155, createdName=liuxiaona, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-10-06 fangcong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643237, encodeId=18fc164323e89, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Oct 06 10:11:41 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333489, encodeId=0b681333489e7, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360552, encodeId=bee113605529a, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417346, encodeId=7987141e34613, content=<a href='/topic/show?id=a2b0394892b' target=_blank style='color:#2F92EE;'>#呋塞米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39489, encryptionId=a2b0394892b, topicName=呋塞米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befb3261155, createdName=liuxiaona, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
    2021-09-17 小华子
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643237, encodeId=18fc164323e89, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Oct 06 10:11:41 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333489, encodeId=0b681333489e7, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360552, encodeId=bee113605529a, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417346, encodeId=7987141e34613, content=<a href='/topic/show?id=a2b0394892b' target=_blank style='color:#2F92EE;'>#呋塞米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39489, encryptionId=a2b0394892b, topicName=呋塞米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befb3261155, createdName=liuxiaona, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643237, encodeId=18fc164323e89, content=<a href='/topic/show?id=97b840365d7' target=_blank style='color:#2F92EE;'>#噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40365, encryptionId=97b840365d7, topicName=噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0e9523156615, createdName=fangcong, createdTime=Wed Oct 06 10:11:41 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1333489, encodeId=0b681333489e7, content=<a href='/topic/show?id=4ce26423802' target=_blank style='color:#2F92EE;'>#水肿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64238, encryptionId=4ce26423802, topicName=水肿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKCRibWHQArPHdSkqP90U1HwwqlGeU7BUgzY240D3v2ibBDJ09ybkGkwOjxz7qRmngZaGlK1taX6hfA/132, createdBy=2e772500094, createdName=小华子, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1360552, encodeId=bee113605529a, content=<a href='/topic/show?id=008b6396165' target=_blank style='color:#2F92EE;'>#氢氯噻嗪#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63961, encryptionId=008b6396165, topicName=氢氯噻嗪)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417346, encodeId=7987141e34613, content=<a href='/topic/show?id=a2b0394892b' target=_blank style='color:#2F92EE;'>#呋塞米#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=39489, encryptionId=a2b0394892b, topicName=呋塞米)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=befb3261155, createdName=liuxiaona, createdTime=Fri Sep 17 13:11:41 CST 2021, time=2021-09-17, status=1, ipAttribution=)]

相关资讯

Brit J Cancer:氢氯噻嗪与皮肤癌风险

由此可见,在亚洲人群中使用氢氯噻嗪似乎对皮肤癌风险是安全的。

J Am Acad Dermatol:丹麦研究:长期用氢氯噻嗪者患皮肤癌的风险增加6倍

一项来自丹麦的研究提示,氢氯噻嗪这种常用的降压药物会导致皮肤癌发生风险增加。究其原因,作者认为,“氢氯噻嗪具有光敏性,从而导致皮肤对紫外线辐射的损害更敏感”。

氢氯噻嗪、胺碘酮、环丙沙星、萘普生等可引发光敏性反应,造成皮肤损伤

晒晒太阳是好事,但有时候就会发生严重晒伤,皮肤出现灼热和瘙痒感、发红、肿胀及起疱等。这里值得注意的是,也许是因为服用的某种药物让你对阳光更敏感。

2019 BIHS科学声明:氢氯噻嗪和皮肤癌风险

2019年3月,英国和爱尔兰高血压学会(BIHS)发布了氢氯噻嗪和皮肤癌风险的科学声明,氢氯噻嗪在临床使用已经超过50年,本文主要介绍了氢氯噻嗪的应用与皮肤癌风险的关系。

英国警示氢氯噻嗪非黑色素瘤皮肤癌风险

英国药品和健康产品管理局(MHRA)2018年11月14日发布消息,警示含氢氯噻嗪类产品长期使用存在累积的剂量依赖性的非黑色素瘤皮肤癌风险,建议服用该类产品的患者定期检查和报告任何可疑的皮肤损害或痣,限制阳光和紫外线照射暴露时间,并采取防晒措施。含氢氯噻嗪的药品主要用于治疗高血压,以及与心脏病、肝病或慢性心功能不全(心力衰竭)相关的水肿。在英国,氢氯噻嗪仅与其他药物固定剂量组合使用,估计约有28,

J INTERN MED:氢氯噻嗪的使用与唇癌的发生风险增加密切相关!

由此可见,氢氯噻嗪的使用与唇癌的发生风险增加密切相关。

Baidu
map
Baidu
map
Baidu
map